Typically respiratory medicines targeting these conditions are based on inhaled corticosteroids (ICS), which have an anti-inflammatory effect, and bronchodilators (such as β2 agonists and muscarinic antagonists/anticholinergics) that relax the muscle in the respiratory tract and increase airflow. These are currently administered as orally inhaled mono- or combination therapies in suspension or dry powder formulations, often with stabilising excipients, and via a multitude of single or multi-dose devices.
Respiratory medicines are however among the most complex drugs to develop and deliver. As a result, just a few products dominate large global markets and directly substitutable generic products face a challenging route to market.
Prosonix believes that the development of future respiratory medicines requires a radical new approach whereby the medicine is designed from the start to meet the specific criteria for oral inhalation, such as:
- Stable API, stable assured formulation and shelf-life
- Minimal or zero requirement for stabilising excipients
- Optimal effectiveness and consistency of delivered dose
- Delivery via simple-to-use and cost-effective devices, reducing treatment cost
- Tailored targeting of drug particles at will
- Enhanced co-location of two drugs in combination therapy
- Optimal therapeutic and safety profile
- Enhanced patient compliance
Prosonix has demonstrated that its ultrasonic particle engineering platform enables the exquisite control of these properties for a range of ICS, LABA and LAMA particles, which form the basis of its own development pipeline. The Company believes that this approach provides the key to unlocking the development of generic and novel respiratory medicines in the future.